LUMO vs. QLI, ONCT, ITRM, FBRX, LSTA, TXMD, BFRG, BIOR, GDTC, and CPIX
Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Qilian International Holding Group (QLI), Oncternal Therapeutics (ONCT), Iterum Therapeutics (ITRM), Forte Biosciences (FBRX), Lisata Therapeutics (LSTA), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), Biora Therapeutics (BIOR), CytoMed Therapeutics (GDTC), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.
Lumos Pharma (NASDAQ:LUMO) and Qilian International Holding Group (NASDAQ:QLI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
Lumos Pharma received 33 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. However, 100.00% of users gave Qilian International Holding Group an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
Lumos Pharma currently has a consensus price target of $18.00, suggesting a potential upside of 527.18%. Given Lumos Pharma's higher possible upside, equities research analysts plainly believe Lumos Pharma is more favorable than Qilian International Holding Group.
Qilian International Holding Group has higher revenue and earnings than Lumos Pharma.
Lumos Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
In the previous week, Lumos Pharma and Lumos Pharma both had 3 articles in the media. Lumos Pharma's average media sentiment score of 0.63 equaled Qilian International Holding Group'saverage media sentiment score.
Qilian International Holding Group has a net margin of 0.00% compared to Lumos Pharma's net margin of -1,659.39%. Qilian International Holding Group's return on equity of 0.00% beat Lumos Pharma's return on equity.
34.0% of Lumos Pharma shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Qilian International Holding Group beats Lumos Pharma on 8 of the 12 factors compared between the two stocks.
Get Lumos Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lumos Pharma Competitors List
Related Companies and Tools
